Chugai Pharmaceutical Management

Management criteria checks 3/4

Chugai Pharmaceutical's CEO is Osamu Okuda, appointed in Mar 2020, has a tenure of 4.17 years. total yearly compensation is ¥298.00M, comprised of 36.2% salary and 63.8% bonuses, including company stock and options. directly owns 0.01% of the company’s shares, worth €4.89M. The average tenure of the management team and the board of directors is 3.6 years and 1.2 years respectively.

Key information

Osamu Okuda

Chief executive officer

JP¥298.0m

Total compensation

CEO salary percentage	36.2%
CEO tenure	4.2yrs
CEO ownership	0.01%
Management average tenure	3.6yrs
Board average tenure	1.2yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Osamu Okuda's remuneration changed compared to Chugai Pharmaceutical's earnings?
Date	Total Compensation	Salary	Company Earnings
Mar 31 2024	n/a	n/a	JP¥326b
Dec 31 2023	n/a	n/a	JP¥325b
Sep 30 2023	n/a	n/a	JP¥337b
Jun 30 2023	n/a	n/a	JP¥327b
Mar 31 2023	n/a	n/a	JP¥316b
Dec 31 2022	JP¥298m	JP¥108m	JP¥374b
Sep 30 2022	n/a	n/a	JP¥371b
Jun 30 2022	n/a	n/a	JP¥389b
Mar 31 2022	n/a	n/a	JP¥387b
Dec 31 2021	JP¥252m	JP¥85m	JP¥303b
Sep 30 2021	n/a	n/a	JP¥256b
Jun 30 2021	n/a	n/a	JP¥231b
Mar 31 2021	n/a	n/a	JP¥211b
Dec 31 2020	JP¥84m	JP¥40m	JP¥215b

Compensation vs Market: Osamu's total compensation ($USD1.95M) is below average for companies of similar size in the German market ($USD5.58M).

Compensation vs Earnings: Osamu's compensation has been consistent with company performance over the past year.

CEO

Osamu Okuda (60 yo)

4.2yrs

Tenure

JP¥298,000,000

Compensation

Dr. Osamu Okuda serves as Representative Director and President at Chugai Pharmaceutical Co., Ltd. since March 30, 2020 and its Chief Executive Officer since March 23, 2021. Dr. Okuda served as Chief Opera...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Osamu Okuda	President	4.2yrs	JP¥298.00m	0.0096% ¥ 4.9m
Iwaaki Taniguchi	Executive VP	less than a year	no data	0.00012% ¥ 61.2k
Toshiya Sasai	Executive of Investor Relations Group & Corporate Communications Department	no data	no data	no data
Masayoshi Higuchi	VP and Head of Quality	less than a year	no data	no data
Shinji Hidaka	Executive Vice President	less than a year	no data	no data
Junichi Ebihara	Executive Vice President	3.3yrs	no data	no data
Yoshiaki Ohashi	SVP & Full-time Audit Supervisory Board Member	9.3yrs	no data	0.0030% ¥ 1.5m
Tetsuya Yamaguchi	Executive VP & Head of PHC Solution Unit	4.3yrs	no data	no data
Yoshiyuki Yano	Executive Vice President	no data	no data	no data
Shigehiro Yamada	Head of Sustainability Department and Full-Time Audit & Supervisory Board Member	no data	no data	0.000060% ¥ 30.6k
Tomoyuki Igawa	Associate VP & Head of Translational Research Division	no data	no data	no data
Kaori Ouchi	Executive Vice President	3.8yrs	no data	no data

3.6yrs

Average Tenure

59.5yo

Average Age

Experienced Management: CUP's management team is considered experienced (3.6 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Osamu Okuda	President	4.2yrs	JP¥298.00m	0.0096% ¥ 4.9m
Iwaaki Taniguchi	Executive VP	less than a year	no data	0.00012% ¥ 61.2k
Yoshiaki Ohashi	SVP & Full-time Audit Supervisory Board Member	3.2yrs	no data	0.0030% ¥ 1.5m
Shigehiro Yamada	Head of Sustainability Department and Full-Time Audit & Supervisory Board Member	1.2yrs	no data	0.000060% ¥ 30.6k
Hitoshi Iikura	VP, Head of Research Division & Director	less than a year	no data	no data
Osamu Nagayama	Honorary Chairman & Senior Advisor	4.2yrs	JP¥211.00m	no data
Franz Humer	Member of the International Advisory Council	no data	no data	no data
Victor Halberstadt	Member of the International Advisory Council	no data	no data	no data
William A. Burns	Member of the International Advisory Council	no data	no data	no data
Henry Nordhoff	Chairman of the International Advisory Council	no data	no data	no data
Fumio Tateishi	Outside Independent Director	1.2yrs	no data	no data
Teresa A. Graham	Director	1.2yrs	no data	no data

1.2yrs

Average Tenure

63yo

Average Age

Experienced Board: CUP's board of directors are not considered experienced ( 1.2 years average tenure), which suggests a new board.

Chugai Pharmaceutical Management

Management criteria checks 3/4

Key information

Recent management updates

Chugai Pharmaceutical Co., Ltd., Annual General Meeting, Mar 30, 2023

Less than half of directors are independent

Less than half of directors are independent

Chugai Pharmaceutical Co., Ltd., Annual General Meeting, Mar 29, 2022

Less than half of directors are independent

Chugai Pharmaceutical Co., Ltd. Announces Management Changes

Recent updates

First quarter 2024 earnings released: EPS: JP¥45.22 (vs JP¥44.68 in 1Q 2023)

Final dividend of JP¥41.00 announced

Now 20% overvalued after recent price rise

Now 20% overvalued after recent price rise

Full year 2023 earnings released: EPS: JP¥198 (vs JP¥228 in FY 2022)

Chugai Pharmaceutical Co., Ltd. Provides Consolidated Non-Audited Earnings Guidance for the Financial Year 2024

Upcoming dividend of JP¥40.00 per share at 1.5% yield

Chugai Pharmaceutical Co., Ltd. to Report Q3, 2024 Results on Oct 25, 2024

Chugai Pharmaceutical Co., Ltd. to Report Fiscal Year 2023 Results on Feb 01, 2024

Chugai Pharmaceutical Co., Ltd. to Report Fiscal Year 2023 Results on Feb 01, 2024

Third quarter 2023 earnings released: EPS: JP¥47.15 (vs JP¥41.21 in 3Q 2022)

Chugai Pharmaceutical Co., Ltd. Provides Consolidated Earnings Guidance for the First Nine Months and Financial Year Ending December 31, 2023

Second quarter 2023 earnings released: EPS: JP¥50.57 (vs JP¥44.00 in 2Q 2022)

Upcoming dividend of JP¥40.00 per share at 1.9% yield

First quarter 2023 earnings released: EPS: JP¥44.68 (vs JP¥80.14 in 1Q 2022)

Chugai Pharmaceutical Co., Ltd., Annual General Meeting, Mar 30, 2023

Full year 2022 earnings released: EPS: JP¥228 (vs JP¥184 in FY 2021)

Chugai Pharmaceutical Co., Ltd. Provides Consolidated Earnings Guidance for the Financial Year 2023

Chugai Pharmaceutical Co., Ltd. Approves Dividend Fiscal Year Ended December 31, 2022, Effective March 31, 2023

Now 20% undervalued

Upcoming dividend of JP¥38.00 per share

Now 21% undervalued after recent price drop

Less than half of directors are independent

Chugai Pharmaceutical Co., Ltd. to Report Fiscal Year 2022 Results on Feb 02, 2023

Chugai Pharmaceutical Co., Ltd. to Report Q1, 2023 Results on Apr 27, 2023

Third quarter 2022 earnings released: EPS: JP¥41.23 (vs JP¥52.32 in 3Q 2021)

Chugai Pharmaceutical Co., Ltd. Provides Consolidated Earnings Guidance for Full Year of Year Ending December 31, 2022

Now 26% undervalued after recent price drop

Chugai Pharmaceutical Co., Ltd. to Report Q2, 2022 Results on Aug 21, 2022

Second quarter 2022 earnings released: EPS: JP¥44.00 (vs JP¥43.02 in 2Q 2021)

Chugai Pharmaceutical Co., Ltd. Provides Consolidated Earnings Guidance for first Six Months and Full Year of Year Ending December 2022

Chugai Pharmaceutical Co., Ltd. to Report Nine Months, 2022 Results on Oct 24, 2022

Upcoming dividend of JP¥38.00 per share

Chugai Pharmaceutical Co., Ltd. to Report Q2, 2022 Results on Jul 21, 2022

Less than half of directors are independent

Chugai Pharmaceutical Co., Ltd. Provides Dividend Guidance for the Fiscal Year 2022

Chugai Pharmaceutical Co., Ltd. to Report Q1, 2022 Results on Apr 25, 2022

Now 22% undervalued after recent price drop

Chugai Pharmaceutical Co., Ltd., Annual General Meeting, Mar 29, 2022

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Chugai Pharmaceutical Co., Ltd. Provides End of Fiscal Year Dividend Guidance for the Year Ending December 2022

Upcoming dividend of JP¥30.00 per share

Less than half of directors are independent

Third quarter 2021 earnings released: EPS JP¥52.32 (vs JP¥36.58 in 3Q 2020)

Second quarter 2021 earnings released: EPS JP¥43.02 (vs JP¥30.89 in 2Q 2020)

Chugai Pharmaceutical Co., Ltd. Obtains Regulatory Approval from the Ministry of Health, Labour and Welfare for the Anti-SARS-CoV-2 Monoclonal Antibody RONAPREVE

Chugai Pharmaceutical Co., Ltd. Announces That Roche Has Been Granted Marketing Authorization from the European Commission

Upcoming dividend of JP¥30.00 per share

CHMP Recommends EU Approval of Chugai's Enspryng (Satralizumab) for Neuromyelitis Optica Spectrum Disorder

Chugai Pharmaceutical Co., Ltd. Provides Earnings Guidance for the Full Year Ending December 31, 2021

Chugai Pharmaceutical Co., Ltd. to Report Q3, 2021 Results on Oct 22, 2021

Atea Pharmaceuticals Announces Chugai In-License of AT-527 from Roche for the Treatment of COVID-19 in Japan

Chugai Pharmaceutical Co., Ltd. Announces Management Changes

Chugai Pharmaceutical Co., Ltd Announces Executive Changes

New 90-day high: €47.00

New 90-day high: €42.20

Upcoming Dividend of JP¥25.00 Per Share

New 90-day high: €39.80

Chugai Pharmaceutical Co., Ltd. to Report Fiscal Year 2020 Results on Feb 04, 2021

Market bids up stock over the past week

New 90-day low: €32.20

Third quarter earnings released

Third-quarter earnings released: Revenue beats expectations

New 90-day low: €36.00

argenx Announces Partnership with Chugai and the Clayton Foundation

Chugai Pharmaceutical Co., Ltd. to Report Q3, 2020 Results on Oct 22, 2020

New 90-day low - €36.40

Chugai Pharmaceutical Co., Ltd. to Report First Half, 2020 Results on Jul 27, 2020

CEO Compensation Analysis